c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target

Pulmonary and systemic hepatocyte and keratinocyte growth factors in patients with chronic obstructive pulmonary disease

(2016) Jaume Sauleda   International Journal of Chronic Obstructive Pulmonary Disease

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

(2015) Marion Zillhardt et al.   NEOPLASIA

Cytoplasmic hepatocyte growth factor immunoreactivity predicting lymph node metastasis in esophageal squamous cell carcinoma

(2014) Yohei Ozawa et al.   Esophagus

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma

(2012) Yin Li et al.   JOURNAL OF SURGICAL ONCOLOGY

Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker

(2011) Dan Zhao et al.   HUMAN PATHOLOGY

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting MET by Tyrosine Kinase Inhibitor Suppresses Growth and Invasion of Nasopharyngeal Carcinoma Cell Lines

(2011) Patrick C. Lau et al.   PATHOLOGY & ONCOLOGY RESEARCH

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

c-MET as a potential therapeutic target and biomarker in cancer

(2011) J. Rafael Sierra et al.   Therapeutic Advances in Medical Oncology

Population-based Survival of Cancer Patients Diagnosed Between 1993 and 1999 in Japan: A Chronological and International Comparative Study

(2010) T. Matsuda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion

(2010) K. D. Grugan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

(2009) L. M. Knowles et al.   CLINICAL CANCER RESEARCH

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase–2 and –7 and E-cadherin

(2009) Yasuyoshi Miyata et al.   HUMAN PATHOLOGY

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma

(2008) J B Tuynman et al.   BRITISH JOURNAL OF CANCER

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE

Protein alterations in ESCC and clinical implications: a review

(2008) D.-C. Lin et al.   DISEASES OF THE ESOPHAGUS